Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Dan Gabriel Duda, Ph.D., D.M.D.

Co-Author

This page shows the publications co-authored by Dan Duda and Rakesh Jain.
Connection Strength

21.748
  1. From the Guest Editors: Role of Tumor Microenvironment in Tumor Progression and Treatment Response: A 30 Years' Journey. Cancer J. 2015 Jul-Aug; 21(4):235-6.
    View in: PubMed
    Score: 0.642
  2. Reply to Ciccolini et al.: Using mathematical modeling to predict response to antiangiogenic therapy in cancer patients. Proc Natl Acad Sci U S A. 2015 Jul 07; 112(27):E3454.
    View in: PubMed
    Score: 0.640
  3. Lessons From 30 Years of Teaching About the Microenvironment of Tumors. Cancer J. 2015 May-Jun; 21(3):137.
    View in: PubMed
    Score: 0.634
  4. Seeds and soil: unraveling the role of local tumor stroma in distant metastasis. J Natl Cancer Inst. 2014 Aug; 106(8).
    View in: PubMed
    Score: 0.602
  5. Can we identify predictive biomarkers for antiangiogenic therapy of cancer using mathematical modeling? J Natl Cancer Inst. 2013 Jun 05; 105(11):762-5.
    View in: PubMed
    Score: 0.553
  6. CXCL12 (SDF1alpha)-CXCR4/CXCR7 pathway inhibition: an emerging sensitizer for anticancer therapies? Clin Cancer Res. 2011 Apr 15; 17(8):2074-80.
    View in: PubMed
    Score: 0.475
  7. Malignant cells facilitate lung metastasis by bringing their own soil. Proc Natl Acad Sci U S A. 2010 Dec 14; 107(50):21677-82.
    View in: PubMed
    Score: 0.466
  8. Premetastatic lung "niche": is vascular endothelial growth factor receptor 1 activation required? Cancer Res. 2010 Jul 15; 70(14):5670-3.
    View in: PubMed
    Score: 0.453
  9. Plasma soluble VEGFR-1 is a potential dual biomarker of response and toxicity for bevacizumab with chemoradiation in locally advanced rectal cancer. Oncologist. 2010; 15(6):577-83.
    View in: PubMed
    Score: 0.450
  10. Biomarkers of antiangiogenic therapy: how do we move from candidate biomarkers to valid biomarkers? J Clin Oncol. 2010 Jan 10; 28(2):183-5.
    View in: PubMed
    Score: 0.436
  11. A comparative study of circulating endothelial cells (CECs) and circulating progenitor cells (CPCs) kinetics in four multidisciplinary phase II studies of antiangiogenic agents. J Clin Oncol. 2008 May 20; 26(15_suppl):3544.
    View in: PubMed
    Score: 0.392
  12. VEGF-targeted cancer therapy strategies: current progress, hurdles and future prospects. Trends Mol Med. 2007 Jun; 13(6):223-30.
    View in: PubMed
    Score: 0.364
  13. A protocol for phenotypic detection and enumeration of circulating endothelial cells and circulating progenitor cells in human blood. Nat Protoc. 2007; 2(4):805-10.
    View in: PubMed
    Score: 0.356
  14. Differential circulation kinetics during antiangiogenic therapy of four distinct blood cell populations expressing endothelial markers. J Clin Oncol. 2006 Jun 20; 24(18_suppl):3038.
    View in: PubMed
    Score: 0.343
  15. Differential CD146 expression on circulating versus tissue endothelial cells in rectal cancer patients: implications for circulating endothelial and progenitor cells as biomarkers for antiangiogenic therapy. J Clin Oncol. 2006 Mar 20; 24(9):1449-53.
    View in: PubMed
    Score: 0.337
  16. Evidence for incorporation of bone marrow-derived endothelial cells into perfused blood vessels in tumors. Blood. 2006 Apr 01; 107(7):2774-6.
    View in: PubMed
    Score: 0.331
  17. Pleiotropy of tissue-specific growth factors: from neurons to vessels via the bone marrow. J Clin Invest. 2005 Mar; 115(3):596-8.
    View in: PubMed
    Score: 0.313
  18. Differential transplantability of tumor-associated stromal cells. Cancer Res. 2004 Sep 01; 64(17):5920-4.
    View in: PubMed
    Score: 0.303
  19. Role of eNOS in neovascularization: NO for endothelial progenitor cells. Trends Mol Med. 2004 Apr; 10(4):143-5.
    View in: PubMed
    Score: 0.294
  20. Role of bone marrow-derived cells in tumor angiogenesis and treatment. Cancer Cell. 2003 Jun; 3(6):515-6.
    View in: PubMed
    Score: 0.278
  21. Placental growth factor promotes tumour desmoplasia and treatment resistance in intrahepatic cholangiocarcinoma. Gut. 2021 Jan 11.
    View in: PubMed
    Score: 0.235
  22. The Current Landscape of Immune Checkpoint Blockade in Hepatocellular Carcinoma: A Review. JAMA Oncol. 2021 Jan 01; 7(1):113-123.
    View in: PubMed
    Score: 0.235
  23. Regorafenib combined with PD1 blockade increases CD8 T-cell infiltration by inducing CXCL10 expression in hepatocellular carcinoma. J Immunother Cancer. 2020 11; 8(2).
    View in: PubMed
    Score: 0.232
  24. Going Beyond VEGF Pathway Inhibition for Antiangiogenic Cancer Therapy: Is Inhibition of the PP2A/B55a Complex the Answer? Circ Res. 2020 08 28; 127(6):724-726.
    View in: PubMed
    Score: 0.229
  25. Combining microenvironment normalization strategies to improve cancer immunotherapy. Proc Natl Acad Sci U S A. 2020 02 18; 117(7):3728-3737.
    View in: PubMed
    Score: 0.221
  26. Dual Programmed Death Receptor-1 and Vascular Endothelial Growth Factor Receptor-2 Blockade Promotes Vascular Normalization and Enhances Antitumor Immune Responses in Hepatocellular Carcinoma. Hepatology. 2020 04; 71(4):1247-1261.
    View in: PubMed
    Score: 0.216
  27. Role of Apelin in Glioblastoma Vascularization and Invasion after Anti-VEGF Therapy: What Is the Impact on the Immune System? Cancer Res. 2019 05 01; 79(9):2104-2106.
    View in: PubMed
    Score: 0.209
  28. Dual endothelin receptor inhibition enhances T-DM1 efficacy in brain metastases from HER2-positive breast cancer. NPJ Breast Cancer. 2019; 5:4.
    View in: PubMed
    Score: 0.205
  29. Differential Association Between Circulating Lymphocyte Populations With Outcome After Radiation Therapy in Subtypes of Liver Cancer. Int J Radiat Oncol Biol Phys. 2018 08 01; 101(5):1222-1225.
    View in: PubMed
    Score: 0.195
  30. Obesity promotes resistance to anti-VEGF therapy in breast cancer by up-regulating IL-6 and potentially FGF-2. Sci Transl Med. 2018 03 14; 10(432).
    View in: PubMed
    Score: 0.193
  31. Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. Nat Rev Clin Oncol. 2018 05; 15(5):325-340.
    View in: PubMed
    Score: 0.193
  32. A cerebellar window for intravital imaging of normal and disease states in mice. Nat Protoc. 2017 Nov; 12(11):2251-2262.
    View in: PubMed
    Score: 0.188
  33. The brain microenvironment mediates resistance in luminal breast cancer to PI3K inhibition through HER3 activation. Sci Transl Med. 2017 05 24; 9(391).
    View in: PubMed
    Score: 0.183
  34. Overcoming sorafenib evasion in hepatocellular carcinoma using CXCR4-targeted nanoparticles to co-deliver MEK-inhibitors. Sci Rep. 2017 03 09; 7:44123.
    View in: PubMed
    Score: 0.180
  35. Corrigendum: Reengineering the Tumor Microenvironment to Alleviate Hypoxia and Overcome Cancer Heterogeneity. Cold Spring Harb Perspect Med. 2016 12 01; 6(12).
    View in: PubMed
    Score: 0.177
  36. Reengineering the Tumor Microenvironment to Alleviate Hypoxia and Overcome Cancer Heterogeneity. Cold Spring Harb Perspect Med. 2016 Dec 01; 6(12).
    View in: PubMed
    Score: 0.177
  37. Phase II and Biomarker Study of Cabozantinib in Metastatic Triple-Negative Breast Cancer Patients. Oncologist. 2017 01; 22(1):25-32.
    View in: PubMed
    Score: 0.176
  38. Dual inhibition of Ang-2 and VEGF receptors normalizes tumor vasculature and prolongs survival in glioblastoma by altering macrophages. Proc Natl Acad Sci U S A. 2016 Apr 19; 113(16):4470-5.
    View in: PubMed
    Score: 0.169
  39. Ang-2/VEGF bispecific antibody reprograms macrophages and resident microglia to anti-tumor phenotype and prolongs glioblastoma survival. Proc Natl Acad Sci U S A. 2016 Apr 19; 113(16):4476-81.
    View in: PubMed
    Score: 0.169
  40. Preclinical Efficacy of Ado-trastuzumab Emtansine in the Brain Microenvironment. J Natl Cancer Inst. 2016 Feb; 108(2).
    View in: PubMed
    Score: 0.164
  41. Role of vascular density and normalization in response to neoadjuvant bevacizumab and chemotherapy in breast cancer patients. Proc Natl Acad Sci U S A. 2015 Nov 17; 112(46):14325-30.
    View in: PubMed
    Score: 0.164
  42. Vascular diseases await translation of blood vessels engineered from stem cells. Sci Transl Med. 2015 Oct 14; 7(309):309rv6.
    View in: PubMed
    Score: 0.164
  43. An orthotopic mouse model of hepatocellular carcinoma with underlying liver cirrhosis. Nat Protoc. 2015 Aug; 10(8):1264-74.
    View in: PubMed
    Score: 0.161
  44. CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice. Hepatology. 2015 May; 61(5):1591-602.
    View in: PubMed
    Score: 0.157
  45. Lessons from anti-vascular endothelial growth factor and anti-vascular endothelial growth factor receptor trials in patients with glioblastoma. J Clin Oncol. 2015 Apr 01; 33(10):1197-213.
    View in: PubMed
    Score: 0.157
  46. Quantum dot/antibody conjugates for in vivo cytometric imaging in mice. Proc Natl Acad Sci U S A. 2015 Feb 03; 112(5):1350-5.
    View in: PubMed
    Score: 0.156
  47. Improved tumor vascularization after anti-VEGF therapy with carboplatin and nab-paclitaxel associates with survival in lung cancer. Proc Natl Acad Sci U S A. 2015 Feb 03; 112(5):1547-52.
    View in: PubMed
    Score: 0.156
  48. Increased perfusion due to vascular normalization improves oxygenation and survival in glioblastoma patients treated with cediranib with or without chemoradiation. Neuro Oncol. 2014 Jul; 16 Suppl 3:iii12.
    View in: PubMed
    Score: 0.150
  49. A phase 1/2 and biomarker study of preoperative short course chemoradiation with proton beam therapy and capecitabine followed by early surgery for resectable pancreatic ductal adenocarcinoma. Int J Radiat Oncol Biol Phys. 2014 Jul 15; 89(4):830-8.
    View in: PubMed
    Score: 0.149
  50. Differential effects of sorafenib on liver versus tumor fibrosis mediated by stromal-derived factor 1 alpha/C-X-C receptor type 4 axis and myeloid differentiation antigen-positive myeloid cell infiltration in mice. Hepatology. 2014 Apr; 59(4):1435-47.
    View in: PubMed
    Score: 0.146
  51. Benefits of vascular normalization are dose and time dependent--letter. Cancer Res. 2013 Dec 01; 73(23):7144-6.
    View in: PubMed
    Score: 0.143
  52. Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation. Proc Natl Acad Sci U S A. 2013 Nov 19; 110(47):19059-64.
    View in: PubMed
    Score: 0.143
  53. Effects of vascular-endothelial protein tyrosine phosphatase inhibition on breast cancer vasculature and metastatic progression. J Natl Cancer Inst. 2013 Aug 21; 105(16):1188-201.
    View in: PubMed
    Score: 0.140
  54. Generation of functionally competent and durable engineered blood vessels from human induced pluripotent stem cells. Proc Natl Acad Sci U S A. 2013 Jul 30; 110(31):12774-9.
    View in: PubMed
    Score: 0.140
  55. Increase in tumor-associated macrophages after antiangiogenic therapy is associated with poor survival among patients with recurrent glioblastoma. Neuro Oncol. 2013 Aug; 15(8):1079-87.
    View in: PubMed
    Score: 0.140
  56. Targeting placental growth factor/neuropilin 1 pathway inhibits growth and spread of medulloblastoma. Cell. 2013 Feb 28; 152(5):1065-76.
    View in: PubMed
    Score: 0.136
  57. Vascular normalization as an emerging strategy to enhance cancer immunotherapy. Cancer Res. 2013 May 15; 73(10):2943-8.
    View in: PubMed
    Score: 0.136
  58. Efficacy, safety, pharmacokinetics, and biomarkers of cediranib monotherapy in advanced hepatocellular carcinoma: a phase II study. Clin Cancer Res. 2013 Mar 15; 19(6):1557-66.
    View in: PubMed
    Score: 0.136
  59. Phase I study of cetuximab, irinotecan, and vandetanib (ZD6474) as therapy for patients with previously treated metastastic colorectal cancer. PLoS One. 2012; 7(6):e38231.
    View in: PubMed
    Score: 0.130
  60. Neovascularization after irradiation: what is the source of newly formed vessels in recurring tumors? J Natl Cancer Inst. 2012 Jun 20; 104(12):899-905.
    View in: PubMed
    Score: 0.129
  61. An isolated tumor perfusion model in mice. Nat Protoc. 2012 Mar 22; 7(4):749-55.
    View in: PubMed
    Score: 0.128
  62. Studying primary tumor-associated fibroblast involvement in cancer metastasis in mice. Nat Protoc. 2012 Mar 22; 7(4):756-62.
    View in: PubMed
    Score: 0.128
  63. Effects of sorafenib on intra-tumoral interstitial fluid pressure and circulating biomarkers in patients with refractory sarcomas (NCI protocol 6948). PLoS One. 2012; 7(2):e26331.
    View in: PubMed
    Score: 0.127
  64. Changes in biomarkers of inflammation and angiogenesis during androgen deprivation therapy for prostate cancer. Oncologist. 2012; 17(2):212-9.
    View in: PubMed
    Score: 0.127
  65. Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev. 2011 Jul; 91(3):1071-121.
    View in: PubMed
    Score: 0.122
  66. Is vasculogenesis crucial for the regrowth of irradiated tumours? Nat Rev Cancer. 2011 Jun 24; 11(7):532.
    View in: PubMed
    Score: 0.121
  67. Safety, Efficacy, and Biomarker Exploration in a Phase II Study of Bevacizumab, Oxaliplatin, and Gemcitabine in Recurrent Müllerian Carcinoma. Clin Ovarian Cancer Other Gynecol Malig. 2011 Jun; 4(1):26-33.
    View in: PubMed
    Score: 0.121
  68. HCC and angiogenesis: possible targets and future directions. Nat Rev Clin Oncol. 2011 May; 8(5):292-301.
    View in: PubMed
    Score: 0.119
  69. Endothelial focal adhesion kinase mediates cancer cell homing to discrete regions of the lungs via E-selectin up-regulation. Proc Natl Acad Sci U S A. 2011 Mar 01; 108(9):3725-30.
    View in: PubMed
    Score: 0.118
  70. Direct evidence for lineage-dependent effects of bone marrow stromal cells on tumor progression. Am J Cancer Res. 2011; 1(2):144-54.
    View in: PubMed
    Score: 0.117
  71. Glioblastoma recurrence after cediranib therapy in patients: lack of "rebound" revascularization as mode of escape. Cancer Res. 2011 Jan 01; 71(1):19-28.
    View in: PubMed
    Score: 0.117
  72. C-X-C receptor type 4 promotes metastasis by activating p38 mitogen-activated protein kinase in myeloid differentiation antigen (Gr-1)-positive cells. Proc Natl Acad Sci U S A. 2011 Jan 04; 108(1):302-7.
    View in: PubMed
    Score: 0.117
  73. Exploratory analysis of early toxicity of sunitinib in advanced hepatocellular carcinoma patients: kinetics and potential biomarker value. Clin Cancer Res. 2011 Feb 15; 17(4):918-27.
    View in: PubMed
    Score: 0.115
  74. A safety and survival analysis of neoadjuvant bevacizumab with standard chemoradiation in a phase I/II study compared with standard chemoradiation in locally advanced rectal cancer. Oncologist. 2010; 15(8):845-51.
    View in: PubMed
    Score: 0.114
  75. Recruitment of myeloid but not endothelial precursor cells facilitates tumor regrowth after local irradiation. Cancer Res. 2010 Jul 15; 70(14):5679-85.
    View in: PubMed
    Score: 0.114
  76. Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J Clin Oncol. 2010 Jun 10; 28(17):2817-23.
    View in: PubMed
    Score: 0.112
  77. Tumor microvasculature and microenvironment: novel insights through intravital imaging in pre-clinical models. Microcirculation. 2010 Apr; 17(3):206-25.
    View in: PubMed
    Score: 0.111
  78. Direct evidence that bevacizumab, an anti-VEGF antibody, up-regulates SDF1alpha, CXCR4, CXCL6, and neuropilin 1 in tumors from patients with rectal cancer. Cancer Res. 2009 Oct 15; 69(20):7905-10.
    View in: PubMed
    Score: 0.108
  79. VEGFR1 activity modulates myeloid cell infiltration in growing lung metastases but is not required for spontaneous metastasis formation. PLoS One. 2009 Sep 18; 4(9):e6525.
    View in: PubMed
    Score: 0.107
  80. VEGFR1-activity-independent metastasis formation. Nature. 2009 Sep 17; 461(7262):E4; discussion E5.
    View in: PubMed
    Score: 0.107
  81. Development of sunitinib in hepatocellular carcinoma: rationale, early clinical experience, and correlative studies. Cancer J. 2009 Jul-Aug; 15(4):263-8.
    View in: PubMed
    Score: 0.106
  82. A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients. Cancer Res. 2009 Jul 01; 69(13):5296-300.
    View in: PubMed
    Score: 0.106
  83. Biomarkers of response and resistance to antiangiogenic therapy. Nat Rev Clin Oncol. 2009 Jun; 6(6):327-38.
    View in: PubMed
    Score: 0.105
  84. Paradoxical effects of PDGF-BB overexpression in endothelial cells on engineered blood vessels in vivo. Am J Pathol. 2009 Jul; 175(1):294-302.
    View in: PubMed
    Score: 0.105
  85. Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study. J Clin Oncol. 2009 Jun 20; 27(18):3020-6.
    View in: PubMed
    Score: 0.105
  86. Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J Clin Oncol. 2009 Jun 20; 27(18):3027-35.
    View in: PubMed
    Score: 0.105
  87. Blockade of VEGFR2 and not VEGFR1 can limit diet-induced fat tissue expansion: role of local versus bone marrow-derived endothelial cells. PLoS One. 2009; 4(3):e4974.
    View in: PubMed
    Score: 0.104
  88. Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice. J Clin Oncol. 2009 May 20; 27(15):2542-52.
    View in: PubMed
    Score: 0.104
  89. Visualizing anti-tumor immune responses in vivo. Dis Model Mech. 2009 Mar-Apr; 2(3-4):107-10.
    View in: PubMed
    Score: 0.103
  90. Characterization of blood vessels in brain autopsies of GBM patients who received antiangiogenic treatment. J Clin Oncol. 2008 May 20; 26(15_suppl):2009.
    View in: PubMed
    Score: 0.098
  91. Sunitinib monotherapy in patients with advanced hepatocellular carcinoma (HCC): Insights from a multidisciplinary phase II study. J Clin Oncol. 2008 May 20; 26(15_suppl):4521.
    View in: PubMed
    Score: 0.098
  92. Correlation of blood and physiologic markers with effect of bevacizumab (BV) with chemoradiation therapy in rectal cancer (RC). J Clin Oncol. 2008 May 20; 26(15_suppl):4096.
    View in: PubMed
    Score: 0.098
  93. A protocol for a lung neovascularization model in rodents. Nat Protoc. 2008; 3(3):378-87.
    View in: PubMed
    Score: 0.095
  94. A protocol for phenotypic detection and characterization of vascular cells of different origins in a lung neovascularization model in rodents. Nat Protoc. 2008; 3(3):388-97.
    View in: PubMed
    Score: 0.095
  95. Differential in vivo potential of endothelial progenitor cells from human umbilical cord blood and adult peripheral blood to form functional long-lasting vessels. Blood. 2008 Feb 01; 111(3):1302-5.
    View in: PubMed
    Score: 0.094
  96. Antiangiogenics: the potential role of integrating this novel treatment modality with chemoradiation for solid cancers. J Clin Oncol. 2007 Sep 10; 25(26):4033-42.
    View in: PubMed
    Score: 0.093
  97. Targeted therapy in rectal cancer. Oncology (Williston Park). 2007 Aug; 21(9):1055-65; discussion 1065, 1070, 1075 passim.
    View in: PubMed
    Score: 0.093
  98. Angiogenesis in brain tumours. Nat Rev Neurosci. 2007 Aug; 8(8):610-22.
    View in: PubMed
    Score: 0.093
  99. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell. 2007 Jan; 11(1):83-95.
    View in: PubMed
    Score: 0.089
  100. Combined vascular endothelial growth factor-targeted therapy and radiotherapy for rectal cancer: theory and clinical practice. Semin Oncol. 2006 Oct; 33(5 Suppl 10):S35-40.
    View in: PubMed
    Score: 0.087
  101. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol. 2006 Jan; 3(1):24-40.
    View in: PubMed
    Score: 0.083
  102. Engineering vascularized tissue. Nat Biotechnol. 2005 Jul; 23(7):821-3.
    View in: PubMed
    Score: 0.080
  103. Quantum dots spectrally distinguish multiple species within the tumor milieu in vivo. Nat Med. 2005 Jun; 11(6):678-82.
    View in: PubMed
    Score: 0.079
  104. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med. 2004 Feb; 10(2):145-7.
    View in: PubMed
    Score: 0.073
  105. Paracrine regulation of angiogenesis and adipocyte differentiation during in vivo adipogenesis. Circ Res. 2003 Oct 31; 93(9):e88-97.
    View in: PubMed
    Score: 0.071
  106. Combining losartan with radiotherapy increases tumor control and inhibits lung metastases from a HER2/neu-positive orthotopic breast cancer model. Radiat Oncol. 2021 Mar 04; 16(1):48.
    View in: PubMed
    Score: 0.059
  107. Vascular dysfunction promotes regional hypoxia after bevacizumab therapy in recurrent glioblastoma patients. Neurooncol Adv. 2020 Jan-Dec; 2(1):vdaa157.
    View in: PubMed
    Score: 0.058
  108. Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma. Clin Cancer Res. 2021 02 15; 27(4):1048-1057.
    View in: PubMed
    Score: 0.058
  109. Antibody-mediated delivery of viral epitopes to tumors harnesses CMV-specific T cells for cancer therapy. Nat Biotechnol. 2020 04; 38(4):420-425.
    View in: PubMed
    Score: 0.055
  110. Bevacizumab Reduces Permeability and Concurrent Temozolomide Delivery in a Subset of Patients with Recurrent Glioblastoma. Clin Cancer Res. 2020 01 01; 26(1):206-212.
    View in: PubMed
    Score: 0.054
  111. A phase II study of cabozantinib alone or in combination with trastuzumab in breast cancer patients with brain metastases. Breast Cancer Res Treat. 2020 Jan; 179(1):113-123.
    View in: PubMed
    Score: 0.054
  112. Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer: A Phase 2 Clinical Trial. JAMA Oncol. 2019 Jul 01; 5(7):1020-1027.
    View in: PubMed
    Score: 0.053
  113. Publisher Correction: Probing tumor microenvironment in patients with newly diagnosed glioblastoma during chemoradiation and adjuvant temozolomide with functional MRI. Sci Rep. 2019 Jun 14; 9(1):8721.
    View in: PubMed
    Score: 0.053
  114. FOLFOX plus ziv-aflibercept or placebo in first-line metastatic esophagogastric adenocarcinoma: A double-blind, randomized, multicenter phase 2 trial. Cancer. 2019 07 01; 125(13):2213-2221.
    View in: PubMed
    Score: 0.052
  115. Probing tumor microenvironment in patients with newly diagnosed glioblastoma during chemoradiation and adjuvant temozolomide with functional MRI. Sci Rep. 2018 11 20; 8(1):17062.
    View in: PubMed
    Score: 0.051
  116. A Phase II and Biomarker Study of Sorafenib Combined with Modified FOLFOX in Patients with Advanced Hepatocellular Carcinoma. Clin Cancer Res. 2019 01 01; 25(1):80-89.
    View in: PubMed
    Score: 0.050
  117. Phase I and Biomarker Study of Plerixafor and Bevacizumab in Recurrent High-Grade Glioma. Clin Cancer Res. 2018 10 01; 24(19):4643-4649.
    View in: PubMed
    Score: 0.049
  118. Phase 2 and biomarker study of trebananib, an angiopoietin-blocking peptibody, with and without bevacizumab for patients with recurrent glioblastoma. Cancer. 2018 04 01; 124(7):1438-1448.
    View in: PubMed
    Score: 0.048
  119. Early changes in glioblastoma metabolism measured by MR spectroscopic imaging during combination of anti-angiogenic cediranib and chemoradiation therapy are associated with survival. NPJ Precis Oncol. 2017; 1.
    View in: PubMed
    Score: 0.046
  120. Use of inhibitors of the renin-angiotensin system is associated with longer survival in patients with hepatocellular carcinoma. United European Gastroenterol J. 2017 Nov; 5(7):987-996.
    View in: PubMed
    Score: 0.045
  121. A phase 2 and biomarker study of cabozantinib in patients with advanced cholangiocarcinoma. Cancer. 2017 06 01; 123(11):1979-1988.
    View in: PubMed
    Score: 0.045
  122. Phase II study of tivozanib, an oral VEGFR inhibitor, in patients with recurrent glioblastoma. J Neurooncol. 2017 02; 131(3):603-610.
    View in: PubMed
    Score: 0.044
  123. Anti-VEGF therapy induces ECM remodeling and mechanical barriers to therapy in colorectal cancer liver metastases. Sci Transl Med. 2016 10 12; 8(360):360ra135.
    View in: PubMed
    Score: 0.044
  124. Efficacy and Biomarker Study of Bevacizumab for Hearing Loss Resulting From Neurofibromatosis Type 2-Associated Vestibular Schwannomas. J Clin Oncol. 2016 05 10; 34(14):1669-75.
    View in: PubMed
    Score: 0.042
  125. PlGF/VEGFR-1 Signaling Promotes Macrophage Polarization and Accelerated Tumor Progression in Obesity. Clin Cancer Res. 2016 06 15; 22(12):2993-3004.
    View in: PubMed
    Score: 0.042
  126. Micelle-Encapsulated Quantum Dot-Porphyrin Assemblies as in Vivo Two-Photon Oxygen Sensors. J Am Chem Soc. 2015 Aug 12; 137(31):9832-42.
    View in: PubMed
    Score: 0.040
  127. Investigation of the Lack of Angiogenesis in the Formation of Lymph Node Metastases. J Natl Cancer Inst. 2015 Sep; 107(9).
    View in: PubMed
    Score: 0.040
  128. A phase I study of cediranib in combination with cilengitide in patients with recurrent glioblastoma. Neuro Oncol. 2015 Oct; 17(10):1386-92.
    View in: PubMed
    Score: 0.040
  129. A Multicenter, Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma Patients. Clin Cancer Res. 2015 Aug 15; 21(16):3610-8.
    View in: PubMed
    Score: 0.040
  130. A phase II and biomarker study of ramucirumab, a human monoclonal antibody targeting the VEGF receptor-2, as first-line monotherapy in patients with advanced hepatocellular cancer. Clin Cancer Res. 2013 Dec 01; 19(23):6614-23.
    View in: PubMed
    Score: 0.036
  131. Magnetic resonance imaging biomarkers in hepatocellular carcinoma: association with response and circulating biomarkers after sunitinib therapy. J Hematol Oncol. 2013 Jul 10; 6:51.
    View in: PubMed
    Score: 0.035
  132. Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy. Proc Natl Acad Sci U S A. 2012 Oct 23; 109(43):17561-6.
    View in: PubMed
    Score: 0.033
  133. A transient parabiosis skin transplantation model in mice. Nat Protoc. 2012 Mar 22; 7(4):763-70.
    View in: PubMed
    Score: 0.032
  134. Phase II study of neoadjuvant bevacizumab and radiotherapy for resectable soft tissue sarcomas. Int J Radiat Oncol Biol Phys. 2011 Nov 15; 81(4):1081-90.
    View in: PubMed
    Score: 0.029
  135. Phase I trial with biomarker studies of vatalanib (PTK787) in patients with newly diagnosed glioblastoma treated with enzyme inducing anti-epileptic drugs and standard radiation and temozolomide. J Neurooncol. 2011 Jun; 103(2):325-32.
    View in: PubMed
    Score: 0.029
  136. VEGF inhibitors in the treatment of cerebral edema in patients with brain cancer. Nat Rev Clin Oncol. 2009 Apr; 6(4):229-36.
    View in: PubMed
    Score: 0.026
  137. Histopathologic findings and establishment of novel tumor lines from spontaneous tumors in FVB/N mice. Comp Med. 2008 Jun; 58(3):253-63.
    View in: PubMed
    Score: 0.025
  138. Antiangiogenic agents for the treatment of glioblastoma. Expert Opin Investig Drugs. 2007 Dec; 16(12):1895-908.
    View in: PubMed
    Score: 0.024
  139. Platelet-derived growth factor receptor-beta in Gorham's disease. Nat Clin Pract Oncol. 2006 Dec; 3(12):693-7.
    View in: PubMed
    Score: 0.022
  140. Platelets and platelet adhesion support angiogenesis while preventing excessive hemorrhage. Proc Natl Acad Sci U S A. 2006 Jan 24; 103(4):855-60.
    View in: PubMed
    Score: 0.021
  141. Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients. J Clin Oncol. 2005 Nov 01; 23(31):8136-9.
    View in: PubMed
    Score: 0.021
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.